A phase II study of primary reirradiation in squamous cell carcinoma of head and neck

被引:64
作者
Langendijk, Johannes A.
Kasperts, Nicolien
Leemans, Charles R.
Doornaert, Patricia
Slotman, Ben J.
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-1081 HV Amsterdam, Netherlands
关键词
head and neck cancer; reirradiation; recurrence; second primary;
D O I
10.1016/j.radonc.2006.02.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background and purpose: In this prospective study, the effect of a second course of primary radiotherapy on locoregional control, survival and toxicity was investigated, in patients who underwent a second course of high dose irradiation for second primary or locoregional recurrent squamous cell head and neck carcinoma (HNSCC) in a previously irradiated area. Patients and methods: A total of 34 patients with second primary (n=26) or locoregional recurrent (n=8) tumours were treated with a second course of high dose radiotherapy. Patients were selected for re-irradiation in case of inoperable and/or unresectable tumours. In most cases, the target volume for re-irradiation was confined to the gross tumour volume (GTV). No elective radiotherapy was applied in the former high-dose area. A total dose of 46 Gy was applied to elective areas with a boost up to 60 Gy with conventional fractionation. The median follow-up period was 32 months. Results: The locoregional control rate after 2 years was 27%. The 3-year overall survival was 22%. The most frequently reported acute side-effect was acute mucositis resulting in swallowing complaints. Pharyngeal and oesophageal late morbidity was also the most important late side-effect. In general, acute and late radiation-induced morbidity remained within acceptable limits. Conclusions: In conclusion, primary re-irradiation appears to be feasible in terms of acute and late radiation-induced toxicity. To improve outcome in terms locoregional control and survival, future studies should be focussed on optimising radiation schedules and the addition of concomitant chemotherapy. (c) 2006 Elsevier Ireland Ltd.
引用
收藏
页码:306 / 312
页数:7
相关论文
共 26 条
[1]
BENCHALAL M, 1995, RADIOTHER ONCOL, V36, P203, DOI 10.1016/0167-8140(95)01620-V
[2]
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer [J].
Brockstein, B ;
Haraf, DJ ;
Stenson, K ;
Sulzen, L ;
Witt, ME ;
Weichselbaum, RW ;
Vokes, EE .
ANNALS OF ONCOLOGY, 2000, 11 (06) :721-728
[3]
BROWMAN GP, 1994, SEMIN ONCOL, V21, P311
[4]
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German cancer society 95-06 prospective randomized trial [J].
Budach, V ;
Stuschke, M ;
Budach, W ;
Baumann, M ;
Geismar, D ;
Grabenbauer, G ;
Lammert, I ;
Jahnke, K ;
Stueben, G ;
Herrmann, T ;
Bamberg, M ;
Wust, P ;
Hinkelbein, W ;
Wernecke, KD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1125-1135
[5]
Conformal re-irradiation of recurrent and new primary head-and-neck cancer [J].
Dawson, LA ;
Myers, LL ;
Bradford, CR ;
Chepeha, DB ;
Hogikyan, ND ;
Teknos, TN ;
Terrell, JE ;
Wolf, GT ;
Eisbruch, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (02) :377-385
[6]
Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients [J].
De Crevoisier, R ;
Bourhis, J ;
Domenge, C ;
Wibault, P ;
Koscielny, S ;
Lusinchi, A ;
Mamelle, G ;
Janot, F ;
Julieron, M ;
Leridant, AM ;
Marandas, P ;
Armand, JP ;
Schwaab, G ;
Luboinski, B ;
Eschwege, F .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3556-3562
[7]
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003 [J].
Fu, KK ;
Pajak, TF ;
Trotti, A ;
Jones, CU ;
Spencer, SA ;
Phillips, TL ;
Garden, AS ;
Ridge, JA ;
Cooper, JS ;
Ang, KK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (01) :7-16
[8]
SIMULTANEOUS CHEMORADIOTHERAPY AS SALVAGE TREATMENT IN LOCOREGIONAL RECURRENCES OF SQUAMOUS HEAD AND NECK-CANCER [J].
GANDIA, D ;
WIBAULT, P ;
GUILLOT, T ;
BENSMAINE, A ;
ARMAND, JP ;
MARANDAS, P ;
LUBOINSKI, B ;
CVITKOVIC, E .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1993, 15 (01) :8-15
[9]
Grau C., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS154, DOI 10.1016/S0360-3016(03)00926-X
[10]
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease [J].
Haraf, DJ ;
Weichselbaum, RR ;
Vokes, EE .
ANNALS OF ONCOLOGY, 1996, 7 (09) :913-918